Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Intravaginal DHEA in Postmenopausal Women
NCT01256671Phase 3Completed
- Sponsor
- Endoceutics
- Start
- Dec 2010
- Primary completion
- Jul 2012
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of prasterone in vaginal atrophy, sponsored by Endoceutics. Primary endpoints: Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium at 52 weeks and Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid Levels at 52 weeks. Started Dec 2010; status: completed.
02
Drugs
prasterone
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on NCT01256671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01256671.